Should new understandings of how cancers develop and could be targeted mean we should change the way the scheme registers cancer drugs?
Articles on Therapeutic Goods Administration
Displaying 41 - 47 of 47 articles
Before the last round of negotiations, only a handful of issues remained in the way of concluding the TPP. A potential deal-breaker for Australia was intellectual property protections for biologics.
The off-label use of medicines is not illegal and it doesn’t mean regulators have specifically “disapproved” its use. But there are a number of issues to consider before using a medicine off-label.
Over the next few weeks, the trade minister will be under intense pressure to renege on the government’s commitment to reject anything in the Trans Pacific Partnership that could undermine the PBS.
The latest part of the TPP to be leaked is its investment chapter. And like almost everything we know about the secretive negotiations for the agreement, it provides plenty of cause for concern.
One of the much-heralded platforms of the Abbott government is its promise to business to reduce red tape and burdensome regulatory obligations. Pharmaceuticals are a multi-billion dollar global industry…
I submitted a complaint about the promotion of “FatBlaster Reducta” (ARTG no: 176366) to the Therapeutic Goods Administration in March 2011. The product is a “complementary medicine” containing an extract…
Top contributors
-
Professor of Pharmaceutical Chemistry, Macquarie University
-
Health activist, Medreach Pty Ltd., Bond University
-
Associate Professor, School of Law, University of Canberra
-
NHMRC Postgraduate Scholar and Fulbright Alumna in Public Health Policy, Monash University
-
Associate Professor of Pharmacology, University of Sydney
-
Professor and Deputy Director, Monash Addiction Research Centre, Monash University
-
Pharmacist and PhD Candidate, University of Sydney
-
Head of School and Dean of Pharmacy, University of Sydney
-
Adjunct professor, Department of Health Policy & Management, George Washington University
-
Pharmacist and PhD Candidate, University of Sydney
-
Professor of Public Health, La Trobe University
-
Professor in Pharmaceutical Policy, School of Pharmacy and Charles Perkins Centre, University of Sydney
-
Biomedical Science/ Law student, Monash University
-
Associate Professor, Urogynaecology Royal Brisbane and Women's and Wesley Hospitals Brisbane, The University of Queensland
-
Tobacco treatment, UNSW